Multiple Sclerosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org Educating Healthcare Professionals about the Medical Use of Cannabis Sat, 29 Jul 2023 17:14:53 +0000 en-US hourly 1 https://wordpress.org/?v=6.2.3 https://www.cannabisclinicians.org/wp-content/uploads/2020/07/cropped-scc-flavicon-32x32.png Multiple Sclerosis – Society of Cannabis Clinicians https://www.cannabisclinicians.org 32 32 Low Doses of β-Caryophyllene Reduced Clinical and Paraclinical Parameters of an Autoimmune Animal Model of Multiple Sclerosis: Investigating the Role of CB2 Receptors in Inflammation by Lymphocytes and Microglial https://www.cannabisclinicians.org/2023/07/29/low-doses-of-%ce%b2-caryophyllene-reduced-clinical-and-paraclinical-parameters-of-an-autoimmune-animal-model-of-multiple-sclerosis-investigating-the-role-of-cb2-receptors-in-inflammation-by-lymphocyt/ Sat, 29 Jul 2023 17:14:53 +0000 https://www.cannabisclinicians.org/?p=28986 Multiple Sclerosis (MS) is a prevalent inflammatory disease in which the immune system plays an essential role in the damage, inflammation, and demyelination of central nervous system neurons (CNS). The cannabinoid receptor type 2 (CB2) agonists possess anti-inflammatory effects against noxious stimuli and elevate the neuronal survival rate. We attempted to analyze the protective impact of low doses of β-Caryophyllene (BCP) in experimental autoimmune encephalomyelitis (EAE) mice as a chronic MS model. Immunization of female C57BL/6 mice was achieved through two subcutaneous injections into different areas of the hind flank with an emulsion that consisted of myelin Myelin oligodendrocyte glycoprotein (MOG)35–55 (150 µg) and complete Freund’s adjuvant (CFA) (400 µg) with an equal volume. Two intraperitoneal (i.p.) injections of pertussis toxin (300 ng) were performed on the animals on day zero (immunizations day) and 48 h (2nd day) after injection of MOG + CFA. The defensive effect of low doses of BCP (2.5 and 5 mg/kg/d) was investigated in the presence and absence of a CB2 receptor antagonist (1 mg/kg, AM630) in the EAE model. We also examined the pro/anti-inflammatory cytokine levels and the polarization of brain microglia and spleen lymphocytes in EAE animals. According to our findings, low doses of BCP offered protective impacts in the EAE mice treatment in a CB2 receptor-dependent way. In addition, according to results, BCP decreased the pathological and clinical defects in EAE mice via modulating adaptive (lymphocytes) and innate (microglia) immune systems from inflammatory phenotypes (M1/Th1/Th17) to anti-inflammatory (M2/Th2/Treg) phenotypes. Additionally, BCP elevated the anti-inflammatory cytokine IL-10 and reduced blood inflammatory cytokines. BCP almost targeted the systemic immune system more than the CNS immune system. Thus, a low dose of BCP can be suggested as a therapeutic effect on MS treatment with potent anti-inflammatory effects and possibly lower toxicity.

The post Low Doses of β-Caryophyllene Reduced Clinical and Paraclinical Parameters of an Autoimmune Animal Model of Multiple Sclerosis: Investigating the Role of CB2 Receptors in Inflammation by Lymphocytes and Microglial appeared first on Society of Cannabis Clinicians.

]]> Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population https://www.cannabisclinicians.org/2023/06/03/multiple-sclerosis-and-use-of-medical-cannabis-a-retrospective-review-of-a-neurology-outpatient-population-2/ Sat, 03 Jun 2023 19:35:49 +0000 https://www.cannabisclinicians.org/?p=28749 Patients diagnosed as having multiple sclerosis (MS) experience a wide range of symptoms requiring pharmacologic management, and many do not achieve adequate symptom control. The purpose of this study was to evaluate the role of medical cannabis (MC) as part of a comprehensive treatment plan for patients with MS. A retrospective medical record review of 141 patients with MS receiving MC for symptom management was conducted. Data were collected for up to 4 follow-up appointments after initiation of MC. Outcomes included changes in MS symptoms, medication changes, adverse events, and changes in cognition and mobility.

The post Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population appeared first on Society of Cannabis Clinicians.

]]> Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo https://www.cannabisclinicians.org/2023/02/22/therapeutic-potential-of-phytocannabinoid-cannabigerol-for-multiple-sclerosis-modulation-of-microglial-activation-in-vitro-and-in-vivo/ Thu, 23 Feb 2023 00:08:20 +0000 https://www.cannabisclinicians.org/?p=27810 Multiple sclerosis (MS) is a widespread chronic neuroinflammatory and neurodegenerative disease. Microglia play a crucial role in the pathogenesis of MS via the release of cytokines and reactive oxygen species, e.g., nitric oxide. Research involving the role of phytocannabinoids in neuroinflammation is currently receiving much attention. Cannabigerol is a main phytocannabinoid, which has attracted significant pharmacological interest due to its non-psychotropic nature. In this research, we studied the effects of cannabigerol on microglial inflammation in vitro, followed by an in vivo study. Cannabigerol attenuated the microglial production of nitric oxide in BV2 microglia and primary glial cells; concomitant treatment of the cells with cannabigerol and telmisartan (a neuroprotective angiotensin receptor blocker) decreased nitric oxide production additively. Inducible nitric oxide synthase (iNOS) expression was also reduced by cannabigerol.

The post Therapeutic Potential of Phytocannabinoid Cannabigerol for Multiple Sclerosis: Modulation of Microglial Activation In Vitro and In Vivo appeared first on Society of Cannabis Clinicians.

]]> Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population https://www.cannabisclinicians.org/2022/12/16/multiple-sclerosis-and-use-of-medical-cannabis-a-retrospective-review-of-a-neurology-outpatient-population/ Fri, 16 Dec 2022 23:10:35 +0000 https://www.cannabisclinicians.org/?p=27303 Patients diagnosed as having multiple sclerosis (MS) experience a wide range of symptoms requiring pharmacologic management, and many do not achieve adequate symptom control. The purpose of this study was to evaluate the role of medical cannabis (MC) as part of a comprehensive treatment plan for patients with MS. A retrospective medical record review of 141 patients with MS receiving MC for symptom management was conducted. Data were collected for up to 4 follow-up appointments after initiation of MC. Outcomes included changes in MS symptoms, medication changes, adverse events, and changes in cognition and mobility.

The post Multiple Sclerosis and Use of Medical Cannabis: A Retrospective Review of a Neurology Outpatient Population appeared first on Society of Cannabis Clinicians.

]]> The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation https://www.cannabisclinicians.org/2022/08/11/the-dynamic-role-of-microglia-and-the-endocannabinoid-system-in-neuroinflammation/ Thu, 11 Aug 2022 14:02:02 +0000 https://www.cannabisclinicians.org/?p=26648 Microglia, the resident immune cells of the brain, can take on a range of pro- or anti-inflammatory phenotypes to maintain homeostasis. However, the sustained activation of pro-inflammatory microglia can lead to a state of chronic neuroinflammation characterized by high concentrations of neurotoxic soluble factors throughout the brain.

The post The Dynamic Role of Microglia and the Endocannabinoid System in Neuroinflammation appeared first on Society of Cannabis Clinicians.

]]> Cannabidiol and Other Cannabinoids in Demyelinating Diseases https://www.cannabisclinicians.org/2022/02/12/cannabidiol-and-other-cannabinoids-in-demyelinating-diseases/ Sat, 12 Feb 2022 13:49:11 +0000 https://www.cannabisclinicians.org/?p=26170 A growing body of preclinical evidence indicates that certain cannabinoids, including cannabidiol (CBD) and synthetic derivatives, may play a role in the myelinating processes and are promising small molecules to be developed as drug candidates for management of demyelinating diseases such as multiple sclerosis (MS), stroke and traumatic brain injury (TBI), which are three of the most prevalent demyelinating disorders. Thanks to the properties described for CBD and its interesting profile in humans, both the phytocannabinoid and derivatives could be considered as potential candidates for clinical use. In this review we will summarize current advances in the use of CBD and other cannabinoids as future potential treatments.

The post Cannabidiol and Other Cannabinoids in Demyelinating Diseases appeared first on Society of Cannabis Clinicians.

]]> Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review https://www.cannabisclinicians.org/2021/02/01/immunomodulatory-potential-of-cannabidiol-in-multiple-sclerosis-a-systematic-review/ Mon, 01 Feb 2021 16:17:49 +0000 https://www.cannabisclinicians.org/?p=21357 Authors Alessia Furgiuele, Marco Cosentino, Marco Ferrari & Franca Marino Published in Journal of Neuroimmune Pharmacology January 2021 Abstract Multiple sclerosis (MS) is the most common chronic autoimmune disease of...

The post Immunomodulatory Potential of Cannabidiol in Multiple Sclerosis: a Systematic Review appeared first on Society of Cannabis Clinicians.

]]> Cannabis Therapeutics and the Future of Neurology https://www.cannabisclinicians.org/2020/08/17/cannabis-therapeutics-and-the-future-of-neurology/ Mon, 17 Aug 2020 15:56:53 +0000 https://www.cannabisclinicians.org/?p=19234 Author: Ethan B. Russo Published in: Frontiers in Integrative Neuroscience  October 2018 Abstract Introduction: Cannabis burst across the Western medicine horizon after its introduction by William O’Shaughnessy in 1838 (O’Shaughnessy, 1838–1840;...

The post Cannabis Therapeutics and the Future of Neurology appeared first on Society of Cannabis Clinicians.

]]> Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression https://www.cannabisclinicians.org/2020/06/15/cbd-for-multiple-sclerosis-immunosupressive-2/ Mon, 15 Jun 2020 11:54:17 +0000 https://www.cannabisclinicians.org/?p=18521 Authors: Nicholas Dopkins, Kiesha Wilson, Kathryn Miranda, Prakash S Nagarkatti and Mitzi Nagarkatti Published in The Journal of Immunology May 2020   Abstract Cannabidiol (CBD) is a nonpsychoactive ingredient from...

The post Efficacy of cannabidiol treatment in experimental MS is due to immunosuppressive activity of myeloid cells in CNS downregulating recruitment of CD4+ T cells, proinflammatory chemokines and gasdermin D expression appeared first on Society of Cannabis Clinicians.

]]> Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. https://www.cannabisclinicians.org/2020/02/17/tetrahydrocannabinol-and-cannabidiol-oromucosal-spray-in-resistant-multiple-sclerosis-spasticity-consistency-of-response-across-subgroups-from-the-savant-randomized-clinical-trial/ Mon, 17 Feb 2020 19:30:41 +0000 http://www.cannabisclinicians.org/?p=16654 Authors: Sven G. Meuth, Thomas Henze, Ute Essner, Christiane Trompke, Carlos Vila Silván Published in International Journal of Neuroscience Abstract Objective: To determine whether differences in disability status, spasticity severity,...

The post Tetrahydrocannabinol and cannabidiol oromucosal spray in resistant multiple sclerosis spasticity: consistency of response across subgroups from the SAVANT randomized clinical trial. appeared first on Society of Cannabis Clinicians.

]]>